Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Nutr Metab Cardiovasc Dis ; 22(3): 292-9, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22032915

ABSTRACT

BACKGROUND AND AIMS: Chronic heart failure (HF) is characterised by a neurohormonal dysfunction associated with chronic inflammation. A role of metabolic derangement in the pathophysiology of HF has been recently reported. Adiponectin, an adipose-tissue-derived cytokine, seems to play an important role in cardiac dysfunction. We investigated the variation of circulating adiponectin in patients with coronary artery disease (CAD), with or without HF, in order to identify its independent predictors. METHODS AND RESULTS: A total of 107 outpatients with CAD were enrolled in the study and divided into three groups: CAD without left ventricular systolic dysfunction (group 1); CAD with left ventricular dysfunction without HF symptoms (group 2) and CAD with overt HF (group 3). Plasma adiponectin was determined by enzyme-linked immunosorbent assay. Adiponectin concentrations increased progressively from group 1 (7.6 ± 3.6 ng ml⁻¹) to group 2 (9.1 ± 6.7 ng ml⁻¹) and group 3 (13.7 ± 7.6 ng ml⁻¹), with the difference reaching statistical significance in group 3 versus 1 and 2 (p < 0.001). A multivariable model of analysis demonstrated that the best predictors of plasma adiponectin were body mass index, N-terminal pro-brain natriuretic peptide and high-density lipoprotein cholesterol. However, even after adjusting for all three independent predictors, the increase of adiponectin in group 3 still remained statistically significant (p = 0.015). CONCLUSION: Our data confirm the rise of adiponectin in overt HF. The levels of circulating adipokine seem to be mainly predicted by the metabolic profile of patients and by biohumoral indicators, rather than by clinical and echocardiographic indexes of HF severity.


Subject(s)
Adiponectin/blood , Coronary Artery Disease/blood , Heart Failure/blood , Outpatients , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Body Mass Index , Chi-Square Distribution , Cholesterol, HDL/blood , Coronary Artery Disease/complications , Coronary Artery Disease/physiopathology , Cross-Sectional Studies , Enzyme-Linked Immunosorbent Assay , Female , Heart Failure/complications , Heart Failure/physiopathology , Humans , Italy , Male , Middle Aged , Multivariate Analysis , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Regression Analysis , Risk Assessment , Risk Factors , Systole , Up-Regulation , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/physiopathology , Ventricular Function, Left
2.
Allergy ; 63(10): 1280-91, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18721246

ABSTRACT

RATIONALE: Several randomized, double-blind, placebo-controlled clinical trials have demonstrated the efficacy of mometasone furoate nasal spray (MFNS) in the treatment of allergic rhinitis (AR) thus allowing for a meta-analysis to determine the overall treatment effect. METHODS: A comprehensive search of the MEDLINE, LILACS, SCOPUS, and the Cochrane Library databases up to 31 October, 2007 was carried out. Randomized, double-blind, placebo-controlled, clinical trials evaluating the efficacy of MFNS in patients with AR compared to placebo were included. Total nasal symptom scores (TNSS), individual nasal symptoms, total non-nasal symptom scores (TNNSS) and nasal airflow were analysed as the standardized mean difference (SMD). Meta-analysis was performed with the random or the fixed effect models depending on heterogeneity, by using revman 5 software. DATA SYNTHESIS: Sixteen of the 113 identified articles met the inclusion criteria. For MFNS efficacy on TNSS, 2998 participants were analysed: 1534 received MFNS and 1464 placebo. Mometasone furoate nasal spray was associated with a significant reduction in TNSS (SMD -0.49, 95% CI: -0.60 to -0.38; P < 0.00001; I(2) = 50.1%). A significant effect on SMD for nasal stuffiness/congestion (-0.41; 95% CI: -0.56 to -0.27), rhinorrhoea (-0.44; 95% CI: -0.66 to -0.21), sneezing (-0.40; 95% CI: -0.57 to -0.23) and nasal itching (-0.39; 95% CI: -0.53 to -0.25) was also demonstrated. Mometasone furoate nasal spray treated subjects also showed a significant reduction in TNNSS (-0.30; 95% CI: -0.43 to -0.18). The proportion of patients with adverse events was similar for MFNS and placebo (0.99; 95% CI: 0.81-1.20; P = 0.91). CONCLUSIONS: This meta-analysis provides a level Ia evidence for the efficacy of MFSN in the treatment of AR vs placebo. Adverse events frequency was similar in both groups.


Subject(s)
Anti-Allergic Agents/administration & dosage , Anti-Allergic Agents/therapeutic use , Pregnadienediols/administration & dosage , Pregnadienediols/therapeutic use , Randomized Controlled Trials as Topic , Rhinitis, Allergic, Perennial/drug therapy , Rhinitis, Allergic, Seasonal/drug therapy , Administration, Intranasal , Anti-Allergic Agents/adverse effects , Double-Blind Method , Humans , Mometasone Furoate , Placebos , Pregnadienediols/adverse effects , Randomized Controlled Trials as Topic/methods
3.
Allergy ; 63(8): 1015-30, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18691305

ABSTRACT

Asthma represents a serious global health problem. People of all ages in countries throughout the world are affected by this chronic airway disorder that, when uncontrolled, can place severe limits on daily life and can even be fatal. Asthma cannot be removed, but asthmatic symptoms can be cured; as for many other chronic diseases, pharmacotherapy is important to reduce the risk of asthma-related mortality, decrease disability and improve symptoms and quality of life. The action of antiasthmatic drugs directly contributes to decrease symptoms severity, improve spirometric results, reduce airway hyperresponsiveness and prevent irreversible airway remodelling. Antiasthmatic therapy is necessary for long-term control of asthma symptoms. Asthma and antiasthmatic drugs can influence patient's quality of life: this is why healthcare systems have recently focused on research studies about Health-Related Quality of Life (HRQL) in asthmatic patients. Numerous validated questionnaires are available and many studies have been performed evaluating HRQL in people affected by asthma, thus testifying a great interest in this topic. The aims of the present review are to examine the scientific literature of the last 4 years (January 2004-December 2007) dealing with the impact of asthma treatments suggested by Global Initiative for Asthma guidelines on patients' quality of life, and to identify the unexplored or not fully investigated areas concerning this issue.


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Asthma/psychology , Quality of Life , Humans , Surveys and Questionnaires , Treatment Outcome
4.
Allergy ; 63(6): 660-9, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18445183

ABSTRACT

Allergic diseases constitute a global health problem, as they have an increasing economic and social impact and, especially, they can deeply interfere with the patients' daily life, being a cause of physical and emotional discomfort. This is why the health-related quality-of-life (HRQoL) has become increasingly important in health care research; in fact, the assessment of the impact the disease and its treatment have on patients, provides a more comprehensive approach in outcome evaluation. Numerous validated questionnaires are available and many studies have been performed evaluating HRQoL in people affected by allergic rhinitis (AR), thus testifying a great interest in this topic. The aims of the present review are: to examine the scientific literature of the last 3 years dealing with the impact of AR treatments suggested by allergic rhinitis and its impact on asthma guidelines on patients' QoL, and to identify the unexplored or not-fully-investigated areas concerning this issue.


Subject(s)
Anti-Allergic Agents/therapeutic use , Quality of Life , Rhinitis, Allergic, Perennial/drug therapy , Rhinitis, Allergic, Seasonal/drug therapy , Anti-Allergic Agents/administration & dosage , Cost of Illness , Desensitization, Immunologic , Drug Administration Routes , Health Services Research , Humans , Immunotherapy , Randomized Controlled Trials as Topic , Surveys and Questionnaires
5.
Monaldi Arch Chest Dis ; 69(2): 78-80, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18837422

ABSTRACT

The anti-IgE antibody omalizumab is currently indicated in severe asthma not controlled by standard drug therapy. Recently, new indications for omalizumab were suggested, which include atopic dermatitis (AD), a skin disorder characterized by elevated levels of IgE. We report the case of a 39-year old woman with severe asthma and severe AD, both resistant to conventional drug treatment. The patient had a IgE level of 1304 kU/L, which exceeded the recommended maximum level for treating asthma with omalizumab (stated in 700 Ku/L) but was far lower than previously reported in cases of AD treated with anti-IgE. The treatment consisted of a dose of omalizumab 375 mg every two weeks, and induced a rapid improvement of asthma, with no need of other drugs after three months, along with a progressive decline of severity of AD, which after five months was completely cured. These findings suggest the usefulness of omalizumab in patients with concomitant severe asthma and AD, also considering the pharmaco-economic balance obtained by withdrawing the multiple drugs used to treat both diseases.


Subject(s)
Anti-Allergic Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Asthma/drug therapy , Dermatitis, Atopic/drug therapy , Adult , Antibodies, Anti-Idiotypic , Antibodies, Monoclonal, Humanized , Asthma/complications , Dermatitis, Atopic/complications , Female , Humans , Omalizumab , Treatment Outcome
6.
J Endocrinol Invest ; 30(8): 684-7, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17923801

ABSTRACT

OBJECTIVE: Adrenal insufficiency due to hypopituitarism can lead to severe hyponatremia with potentially fatal consequences. Prompt diagnosis and adequate hormonal replacement therapy are essential to block an otherwise unfavorable course and to re-establish a healthy life. Unfortunately, this condition is often misdiagnosed. DESIGN: Case report. SETTING: Intensive Care Unit of a teaching hospital. PATIENT: A 76-yr-old man with refractory hypotension, acute myocardial infarction, and left ventricular dysfunction, secondary to severe chronic pan-hypopituitarism, associated with severe hyponatremia. METHODS AND MAIN RESULTS: The patient underwent mechanical ventilation and continuous venous-venous hemodiafiltration, for severe respiratory and renal insufficiency. A hormonal replacement therapy with T4, hydrocortisone, and nandrolone was started and the patient was discharged to a rehabilitation facility after 31 days of hospitalization. CONCLUSIONS: Hypopituitarism with secondary adrenal insufficiency is often misdiagnosed at an early stage and a high degree of suspicion is necessary for early diagnosis. Determination of plasma cortisol level in patients with hyponatremia not explained by other causes should always be obtained.


Subject(s)
Adrenal Insufficiency/complications , Hyponatremia/etiology , Hypopituitarism/complications , Adrenal Insufficiency/blood , Adrenal Insufficiency/diagnosis , Aged , Electrocardiography , Humans , Hydrocortisone/blood , Hyponatremia/blood , Hyponatremia/diagnosis , Hypopituitarism/blood , Hypopituitarism/diagnosis , Male , Severity of Illness Index
7.
Article in English | MEDLINE | ID: mdl-16689184

ABSTRACT

Even though chronic cough (CC) is a bothersome symptom, only a small number of studies have evaluated its specific burden on health-related quality of life (HRQL). The aim of the present study was to assess how the presence of CC interferes with HRQL. A total of 95 outpatients were enrolled during medical consultation at our "Chronic Cough Center". A health status measure (SF-36) and a new HRQL questionnaire specific for CC (CCIQ) were administered before the initial visit. Compared to the reference sample, CC patients reported significantly lower scores in 5 of 8 SF-36 domains: Social functioning (t=10.292), Physical role limitation (t=9.667), Emotional role limitation (t=7.712), General health (t=5.154) and Vitality (t=4.426). The analysis of CCIQ scores showed a disability due to CC, independent of its etiology. The greatest disabilities were observed in the Social relationship (58.33) domain, followed by Sleep/Concentration (54.26), Mood (51.49) and Daily activities (47.69). Sleep, disturbing the partner, and irritability were the three outstanding aspects, affecting 80% of patients. These results show that CC has a high negative impact on HRQL, and they further suggest that the CCIQ is a useful tool for obtaining a global evaluation including its impact and therapeutic options.


Subject(s)
Cough/psychology , Quality of Life , Surveys and Questionnaires , Affect , Asthma/complications , Asthma/psychology , Chronic Disease/psychology , Cough/etiology , Female , Gastroesophageal Reflux/complications , Gastroesophageal Reflux/psychology , Humans , Interpersonal Relations , Male , Nose Diseases/complications , Nose Diseases/psychology , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Disease, Chronic Obstructive/psychology , Sleep
8.
Biochim Biophys Acta ; 1312(1): 27-38, 1996 Jun 05.
Article in English | MEDLINE | ID: mdl-8679713

ABSTRACT

Autocrine/paracrine stimulation of cell growth by members of the fibroblast growth factor (FGF) family of polypeptides is dependent upon extracellular interactions with specific high affinity receptors at the cell surface. Acidic FGF (FGF-1) lacks a classical signal sequence for secretion, suggesting that intrinsic levels of this mitogen may not stimulate cell growth and utilizes a non-classical pathway to gain access to the extracellular compartment. To evaluate the biological potential of intracellular FGF-1 more rigorously, human cDNA sequences for the growth factor were introduced into primary murine embryonic fibroblasts using retrovirally mediated gene transfer. Heparin affinity, Western analysis, mitogenic assays, in situ immunohistochemical techniques, induction of tyrosine phosphorylation and antibody inhibition studies were used to demonstrate functionality of the FGF-1 transgene in this experimental model. Under normal culture conditions, cells constitutively expressing intracellular FGF-1 exhibited a slight growth advantage. In contrast, when maintained in reduced serum, these cells adopted a transformed phenotype and demonstrated an enhanced growth potential, induction of FGF-specific phosphotyrosyl proteins and the nuclear association of the growth factor. Analysis of the conditioned media from these stressed cells indicated that serum starvation induces the secretion of FGF-1 as latent high molecular mass complexes requiring reducing agents to activate its full biological potential.


Subject(s)
Fibroblast Growth Factor 1/biosynthesis , Fibroblasts/metabolism , Amino Acid Sequence , Animals , Base Sequence , Blood , Cell Division , Cells, Cultured , Cortactin , Culture Media, Conditioned/chemistry , DNA, Complementary , Fibroblast Growth Factor 1/analysis , Fibroblast Growth Factor 1/chemistry , Fibroblast Growth Factor 1/genetics , Fibroblast Growth Factor 1/metabolism , Fibroblasts/chemistry , Fibroblasts/cytology , Gene Transfer Techniques , Humans , Mice , Microfilament Proteins/analysis , Mitogens , Molecular Sequence Data , Molecular Weight , Phosphorylation , Proto-Oncogene Proteins pp60(c-src)/analysis , Tyrosine/metabolism
9.
J Am Geriatr Soc ; 43(4): 389-94, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7706629

ABSTRACT

OBJECTIVE: To determine whether advanced age is an independent prognostic factor that may increase the risk of complications and reduce the immediate and long-term survival after treatment with intra-aortic balloon pumping (IABP) for acute ischemic heart disease. DESIGN: Retrospective analysis of a clinical series and long-term follow-up study. PATIENTS: A total of 142 patients (age range 23-86 years) in whom IABP was indicated following a standardized protocol. MEASUREMENTS: Univariate analysis of the association between age and anamnestic, clinical, and hemodynamic data significantly affecting prognosis; multivariate logistic regression analysis of variables showing significant associations. RESULTS: IABP-related complications were independent of age. At univariate analysis, pre-existing, noncardiac, associated conditions (chronic renal failure, stroke, bronchopulmonary disease) (P < .001), an indication to IABP for hemodynamic complications of acute myocardial infarction rather than for medically refractory myocardial ischemia (P < .001), a lack in hemodynamic response to IABP (P < .002), a prolonged delay to IABP initiation (P < .003), and advanced age (P < .025) were all predictors of in-hospital mortality. However, older patients were also more frequently affected by chronic comorbid conditions and by acute left ventricular failure as an indication to IABP. When these variables were entered into logistic regression models, the association between age and mortality was no longer statistically significant. Similarly, advancing age was associated (P < .012) with an increased mortality rate during an average follow-up of 94 +/- 9 months, but, again, such a significant association disappeared when simultaneously adjusting for New York Heart Association functional class, which was the single most important predictor of long-term mortality. CONCLUSIONS: Several anamnestic and clinical variables, rather than advanced age itself, are independent, prognostic factors negatively affecting the outcome of treatment with IABP. Technique-related complications are independent of age. Thus, old age should not be considered as a criterion to exclude any patient, a priori, from the potential benefits of this type of cardiocirculatory assistance.


Subject(s)
Intra-Aortic Balloon Pumping/mortality , Myocardial Ischemia/therapy , Acute Disease , Adult , Age Factors , Aged , Aged, 80 and over , Female , Follow-Up Studies , Hospital Mortality , Humans , Male , Middle Aged , Myocardial Ischemia/complications , Myocardial Ischemia/mortality , Prognosis , Retrospective Studies , Survival Analysis , Treatment Outcome
10.
J Hum Hypertens ; 18(12): 897-903, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15241442

ABSTRACT

The present investigation was aimed at determining the prevalence and the blood pressure (BP) profile of isolated ambulatory hypertension, defined as an elevated ambulatory BP with normal office blood pressure, in a series of 1488 consecutive outpatients referred for routine clinical evaluation of suspected or established arterial hypertension. All patients underwent both office BP (OBP) measurement by a physician and 24-h ambulatory blood pressure monitoring (ABPM). Using OBP values (cutoff for diagnosis of hypertension >/=140/90 mmHg) and daytime ABPM (cutoff for diagnosis of hypertension >/=135/85 mmHg), patients were classified into eight subgroups. In the whole series we found that, independent of treatment status, the prevalence of isolated ambulatory hypertension exceeded 10%. More importantly, 45.3% of individuals who presented with normal OBP values, showed elevated BP at ABPM. Night-time BP, 24-h pulse pressure, and BP variability were significantly higher in isolated ambulatory hypertensives than in normotensive or in white-coat hypertensive individuals. Therefore, isolated ambulatory hypertension is characterized by a blood pressure profile that is similar to that observed in sustained hypertension. These findings suggest that isolated ambulatory hypertension is very common and probably the indications for ABPM should be more extensive in outpatients referred to hypertensive centre.


Subject(s)
Blood Pressure Monitoring, Ambulatory , Blood Pressure , Hypertension/physiopathology , Outpatients , Academic Medical Centers , Adult , Aged , Aged, 80 and over , Blood Pressure Determination , Female , Humans , Hypertension/etiology , Male , Middle Aged , Multivariate Analysis , Office Visits , Referral and Consultation , Sex Factors , Smoking
12.
Ann Ig ; 1(6): 1389-417, 1989.
Article in Italian | MEDLINE | ID: mdl-2484474

ABSTRACT

Kampene is a roughly 10,000 inhabitants village in Kivu, eastern region of Republic of Zaire. The equatorial rainforest in river Zaire basin surrounds it, far from the main and most crowded roads. Climate is warm and wet, rainfalls constant throughout ten months a years. Eighty seven per cent of the population of Kampene and of its administrative district (around 100,000 inhabitants) work in agriculture. Most of the remainder gets by on mineral search and mining (tin, cassiterite, gold). Health facilities and their organisation should be set up as according to Zaire Health Planning, worked out of 1977 Alma Ata Conference's guidelines on Primary Health Care, but actually they are hard to be implemented because of the wide territory, of the scattered settlements to be served, because of infrastructure and funds shortages. High children death ratio (roughly from 104 to 200/1000 altogether, short mean lifetimes and generally morbidity are caused by: parasitoses (malaria, filariasis, gut worms, bilharziosis, amebiasis), bacterial infections (breast feeding babies' toxic enteritis, tuberculosis, salmonellosis, shigellosis, gonococcosis, tetanus, epidemic meningitis), viral diseases (measles, poliomyelitis, virus B hepatitis, AIDS), protein-energy malnutrition, obstetric pathology (uterus fractures, ectopic pregnancy, obstructed labour). The management of Kampene Hospital is taken over by a Zaire-Italian team, according to the "Progetto Socio-Sanitario a Kampene", project carried out by Centro Volontari Marchigiani, a not-governmental organisation recognized and financed by Italian Foreign Office. The utilization of Kampene hospital wards has been investigated throughout 20 months (since 1/1/1986 to 31/8/1987) by working some parameters out: numbers of admissions, numbers of hospital days, man length of stay, bed occupancy rate, turnover index for bed. The utilisation of outpatient clinic has been investigated by means of the number of outpatients and outpatients per health operator ratio. Moreover the death rate for each ward has been appraised. These data show that wards and outpatient clinics are largely utilized; but a better redistribution of beds from Gynecology to Medicine and Pediatrics wards is suggested. The importance of a steady health team on the run stands out. Moreover the data stress the high death rates both of measles epidemics and protein-energy malnutrition (21.4% so far). In conclusion mother-child clinic is not yet satisfactory and should be better developed; protein-energy malnutrition urges food supply and deeper food consumption education projects to be supported.


PIP: The registry of patients at the hospital of Kampene, Zaire, covering the period 1986-87 was examined to determine the hospital's rate of utilization and accessibility, to evaluate mortality, and to ascertain the prevalence of infectious diseases. The 1986 data of the hospital laboratory indicated a high incidence of infectious and parasitic diseases: ancylostomiasis (33.6%); ascariasis (22.9%); schistosomiasis (3.4%); multiple intestinal parasitic infections (10.9%); malaria (43%), often chloroquine-resistant; filariasis (70.8%); and alcohol-acid resistant tuberculosis bacilli (15%). Sexually-transmitted diseases such as vaginitis (80%) were caused by polygamy, prostitution, and promiscuity, HIV serodiagnosis could not be performed because of a lack of equipment. A high infant mortality rate was caused by neonatal tetanus, toxic gastroenteritis, measles (5.1% lethality: 2 died out of 39 cases), and epidemic cerebrospinal meningitis. Malnutrition caused kwashiorkor and avitaminosis. 792 births were registered at the maternity ward in 1986: 52.8% were male and 47.2% were female; 48 (6.1%) were stillborn or died in the following days; 104 (13.1%) were born prematurely; and 24 (3.1%) were twins. Cesarean section was performed in 43 cases (5.4%). There was a total of 15,099 outpatient visits during a 1-year period. The bed occupancy rate of the surgical ward ranged between .7 and .8 during 1987. Recovery and hospitalization days per doctor or health assistant were very high compared to Italian standards. The lethality of malaria was a high 1.8%, but malnutrition rated even higher: 21.4%. The utilization of the hospital was high, Maternal-child protection measures, especially in the area of nutrition, require the training of community health workers and traditional birth attendants; however, cost-benefit considerations limit resources and the implementation of primary health care is curtailed by economic and cultural factors.


Subject(s)
Health Services Administration , Health Status , Acquired Immunodeficiency Syndrome/epidemiology , Adult , Ambulatory Care Facilities/statistics & numerical data , Cause of Death , Child , Child, Preschool , Democratic Republic of the Congo/epidemiology , Diagnosis-Related Groups , Female , Health Services/statistics & numerical data , Health Services/supply & distribution , Health Workforce , Humans , Infant , Infant Mortality , Infant, Newborn , Infections/epidemiology , International Cooperation , Italy , Male , Maternal-Child Health Centers/statistics & numerical data , Pregnancy , Protein-Energy Malnutrition/epidemiology , Socioeconomic Factors , Tropical Medicine
13.
Ann Ig ; 1(5): 943-56, 1989.
Article in Italian | MEDLINE | ID: mdl-2483914

ABSTRACT

The Authors, after outlining the problem of elderly people, refer to data from their research defining precisely the particular demographic-social situations of the elderly in the city of Camerino. Research, using the same questionnaire, was carried out into the most frequent state of health and pathology of elderly people living in the city of Camerino. The most significant data provided some points for discussion as well as considerations relative to prevention and care in old age. The occasion was taken for stimulating our Society to not neglect elderly people but rather to find the right solutions for maintaining their standard of living at the highest level possible.


Subject(s)
Aged , Health Status , Social Class , Female , Health Surveys , Humans , Italy/epidemiology , Male , Middle Aged , Morbidity , Surveys and Questionnaires , Urban Population
15.
Minerva Anestesiol ; 76(6): 405-12, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20473253

ABSTRACT

AIM: The beneficial role of hemofiltration with immobilized polymyxin-B fiber (PMX) columns in sepsis, especially sepsis due to gram-negative bacteria, has previously been emphasized. Although the efficacy of PMX-B fiber-mediated hemofiltration in reducing plasma levels of cytokines has been reported, other studies did not confirm this observation. Here we report the effects of PMX-B fiber-mediated hemofiltration on outcome and cytokine plasma levels in patients with abdominal sepsis. METHODS: Twelve consecutive patients admitted to the Intensive Care Unit (October 2006-December 2007) for severe sepsis/septic shock from abdominal infection were treated with standard therapy and 2 cycles of hemofiltration with PMX cartridges. Clinical data and plasma levels of IL-6, IL-10 and TNF-a were measured 24 hours before and after PMX treatment. RESULTS: Plasma concentrations (pg/mL) of IL-6, IL-10 and TNF-a were significantly lower after hemofiltration with a PMX fiber column (279.9+/-69.2 vs. 130.9+/-18.4, 166.4+/-36.7 vs. 45.5+/-12.2, 83.1+/-13.5 vs. 23.9+/-5.1 pg/mL, respectively; P<0.05). After treatment, patients required lower doses of norepinephrine (0.3+/-0.1 vs. 0.8+/-0.1 mg/kg/min) and reduced lactate levels, recovery of respiratory function and improved Simplified Organ Failure Assessment (SOFA) scores. After 28 days, 6 patients (50%) had survived. Subgroup analysis demonstrated that survivors had higher IL-6 and lower IL-10 and TNF-a pre-treatment plasma levels (pg/mL) compared with deceased patients (324.4+/-41.1 vs.235.3+/-38.4; 98.5+/-16.1 vs. 234.3+/-48.6, 44.5+/-9.0 vs.121.6+/-52.3 pg/mL, respectively; P<0.05). No adverse events imputable to the treatment were recorded. CONCLUSION: Hemofiltration with a PMX fiber column was able to reduce plasma levels of IL-6, IL-10 and TNF-a, especially in patients surviving at 28 days. Use of the technique was associated with lower norepinephrine support and an increased PaO2/FiO2 ratio.


Subject(s)
Hemoperfusion , Interleukin-10/blood , Interleukin-6/blood , Polymyxin B , Sepsis/blood , Sepsis/therapy , Tumor Necrosis Factor-alpha/blood , Abdomen , Adult , Aged , Female , Hemoperfusion/methods , Humans , Male , Middle Aged , Pilot Projects
16.
Allergy ; 62(4): 359-66, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17362245

ABSTRACT

The objective of the study is to assess the efficacy of the nonsedating antihistamine, desloratadine, in the treatment of allergic rhinitis (AR). A search of MEDLINE, EMBASE, LILACS, and CINAHL databases was undertaken from January, 1966 to May, 2006. Double-blind, randomized, controlled studies of desloratadine in the treatment of AR in adult patients were carried out. The measured outcomes included the total symptoms score, the total nasal symptoms score, nasal airflow, and inflammatory markers (nasal eosinophils, nasal interleukin-4). The analysis included the calculation of standardized mean difference (SMD). A total of 57 studies were analyzed, and 13 randomized, double-blind, controlled trials were included in the meta-analysis. The trials included 3108 subjects who had completed studies involving desloratadine. There was significant heterogeneity among the study results, because of differing study methodologies. Desloratadine was associated with significant reductions in total symptoms scores (SMD -1.63; 95% CI -2.75 to -0.51; P = 0.004) and total nasal symptoms score (SMD -0.66; 95% CI -0.91 to -0.42; P < 0.001), when compared with placebo. Analysis of objective data on nasal blockage demonstrated a significant improvement in nasal airflow with desloratadine, when compared with placebo (SMD 0.32; 95% CI 0.10 to 0.55; P = 0.005). A benefit favoring desloratadine over placebo in terms of nasal eosinophil levels was also noted in the analysis. This meta-analysis confirms the reduction of AR symptoms and improvement in nasal airflow seen in individual studies of desloratadine. Objective improvements in nasal airflow, total symptoms, and total nasal symptoms seen with desloratadine are supported by Ia evidence.


Subject(s)
Histamine H1 Antagonists, Non-Sedating/therapeutic use , Loratadine/analogs & derivatives , Rhinitis/drug therapy , Double-Blind Method , Humans , Hypersensitivity/drug therapy , Loratadine/therapeutic use , Nasal Obstruction/drug therapy , Randomized Controlled Trials as Topic , Treatment Outcome
17.
Int J Chron Obstruct Pulmon Dis ; 2(3): 335-45, 2007.
Article in English | MEDLINE | ID: mdl-18229572

ABSTRACT

Respiratory tract infections (RTIs) represent a serious problem because they are one of the most common cause of human death by infection. The search for the treatment of those diseases has therefore a great importance. In this study we provide an overview of the currently available treatments for RTIs with particular attention to chronic obstructive pulmonary diseases exacerbations and recurrent respiratory infections therapy and a description of bacterial lysate action, in particular making reference to the medical literature dealing with its clinical efficacy. Those studies are based on a very large number of clinical trials aimed to evaluate the effects of this drug in maintaining the immune system in a state of alert, and in increasing the defences against microbial infections. From this analysis it comes out that bacterial lysates have a protective effect, which induce a significant reduction of the symptoms related to respiratory infections. Those results could be very interesting also from an economic point of view, because they envisage a reduction in the number of acute exacerbations and a shorter duration of hospitalization. The use of bacterial lysate could therefore represent an important means to achieve an extension of life duration in patients affected by respiratory diseases.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Cell Extracts/therapeutic use , Pulmonary Disease, Chronic Obstructive/drug therapy , Respiratory Tract Infections/prevention & control , Adjuvants, Immunologic/pharmacology , Bacteria , Cell Extracts/pharmacology , Evidence-Based Medicine , Humans , Italy , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Disease, Chronic Obstructive/immunology , Pulmonary Disease, Chronic Obstructive/physiopathology , Randomized Controlled Trials as Topic , Respiratory Tract Infections/etiology , Respiratory Tract Infections/immunology , Respiratory Tract Infections/physiopathology , Treatment Outcome
18.
Allergy ; 62(6): 605-10, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17508963

ABSTRACT

The most fascinating options of the new asthma treatments are probably represented by monoclonal antibodies. In fact, these molecules are virtually able to interact with whatever specific antigen. Anyway, it is mandatory to understand the limits of this group of molecules, in terms of both efficacy and safety. In this review, we have analyzed different ways of interfering along the course of the cascade of the allergic reaction, targeting different molecules (CD4, TNF-alpha, IL-4, IL-5, IL-10, IL-12, endothelial adhesion molecules, IgE), showing the efficacy and the risks of each kind of treatment. In the end, we focused our attention on omalizumab, the monoclonal antibody targeting IgE. Although with some restrictions, represented by the high costs and the limitation of its use only to a specific subset of patients affected by allergic asthma, at present anti-IgE appear to be the only 'magic bullet' for the treatment of allergic asthma. In fact, it proved to reduce exacerbations and symptom scores, and to improve quality of life, with a very good safety profile.


Subject(s)
Anti-Asthmatic Agents/pharmacology , Antibodies, Monoclonal/therapeutic use , Asthma/therapy , Anti-Asthmatic Agents/chemistry , Anti-Asthmatic Agents/immunology , Antibodies, Anti-Idiotypic , Antibodies, Monoclonal, Humanized , Clinical Trials as Topic , Humans , Immunoglobulin E/immunology , Omalizumab , Quality of Life
19.
Oral Dis ; 13(4): 419-25, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17577330

ABSTRACT

OBJECTIVE: Orofacial granulomatosis (OFG) is a rare condition characterized by non-caseating granulomas in the orofacial region. Protease-Activated Receptors (PARs) play a role in inflammatory diseases in diverse human tissues. The aim of the study was to investigate the expression of PAR-1, PAR-2, MMP-2, MMP-9, COX-1, and COX-2 in tissues taken from OFG patients. METHODS: PAR-1, PAR-2, MMP-2, MMP-9, COX-1, and COX-2 expression was evaluated by immunohistochemistry in biopsies taken from oral Crohn's disease (five cases), Melkersson-Rosenthal syndrome (MRS) (six cases), cheilitis granulomatosa (five cases) and normal oral mucosa (five cases). RESULTS: PAR-1 was observed in mononuclear inflammatory cells in edematous/lichenoid lesions, whereas a strong PAR-2 immunostaining was detected in epithelioid histiocytes and giant cells in granulomatous lesions, irrespective of the clinical features (Crohn vs MRS). MMPs and COX-2 were expressed in the inflammatory component of edematous/lichenoid lesions and markedly overexpressed in granulomatous lesions. COX-1 was weakly and variably expressed in both edematous/lichenoid and granulomatous lesions. CONCLUSION: Thus, PAR-1 and PAR-2 expressions were related to the intensity and type of inflammatory response but not to the type of clinical lesion. Simultaneous overexpression of PARs, MMPs and COXs suggests synergism among these proinflammatory receptors and enzymes.


Subject(s)
Granulomatosis, Orofacial/pathology , Receptor, PAR-1/analysis , Receptor, PAR-2/analysis , Adolescent , Adult , Aged , Child , Crohn Disease/pathology , Cyclooxygenase 1/analysis , Cyclooxygenase 2/analysis , Edema/pathology , Epithelioid Cells/pathology , Female , Giant Cells/pathology , Histiocytes/pathology , Humans , Leukocytes, Mononuclear/pathology , Lichenoid Eruptions/pathology , Male , Matrix Metalloproteinase 2/analysis , Matrix Metalloproteinase 9/analysis , Melkersson-Rosenthal Syndrome/pathology , Middle Aged , Mouth Diseases/pathology , Mouth Mucosa/pathology , Retrospective Studies
20.
J Pathol ; 212(4): 440-9, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17597495

ABSTRACT

Protease-activated receptor (PAR)-1 and PAR-2 are reported to contribute to the fibrotic process in a number of organs, including lung, liver, pancreas, and kidney. The aim of this study was to localize expression and biological activity of PAR-1 and PAR-2 in normal and pathological cutaneous scars. First, we investigated the immunohistochemical expression of PAR-1 and PAR-2 proteins in a series of human normal scars (NS, n = 10), hypertrophic scars (HS, n = 10), and keloids (K, n = 10). Expression of PAR-1 and PAR-2 was observed in all types of scar. Specifically, in HS and K, diffuse PAR-1 and PAR-2 positivity was found in dermal cellular areas composed of myofibroblasts, while no or minor staining was observed in the scattered fibroblasts embedded in abundant extracellular matrix in the context of the more collagenous nodules, irrespective of the type of scar. The hyperplastic epidermis overlying K was also found to be strongly PAR-1 and PAR-2 positive, whilst in most NS and HS the epidermis was faintly to moderately stained. Second, ribonuclease protection assay on paraffin-embedded specimens showed overexpression of PAR-1 and PAR-2 mRNA in K compared to NS and HS. Third, cultured human fibroblasts exposed to TGF-beta1 expressed a myofibroblast phenotype associated with overexpression of PAR-2, while PAR-1 expression was unaffected. Intracellular Ca(2+) mobilization by PAR-2 agonists in myofibroblasts was increased as compared to fibroblasts, whereas the effect of PAR-1 agonists was unchanged. Our in vivo study indicates that PAR-1 and PAR-2 are expressed in cells involved in physiological and pathological scar formation and suggests that in vitro overexpression and exaggerated functional response of PAR-2 may play a role in the function of myofibroblasts in scar evolution from a physiological repair process to a pathological tissue response.


Subject(s)
Cicatrix/metabolism , Receptor, PAR-1/metabolism , Receptor, PAR-2/metabolism , Adolescent , Adult , Aged , Calcium/metabolism , Cells, Cultured , Cicatrix/pathology , Cicatrix, Hypertrophic/metabolism , Cicatrix, Hypertrophic/pathology , Female , Fibroblasts/drug effects , Fibroblasts/metabolism , Gene Expression Regulation/drug effects , Humans , Keloid/metabolism , Keloid/pathology , Male , Middle Aged , RNA, Messenger/genetics , Receptor, PAR-1/genetics , Receptor, PAR-2/genetics , Skin/metabolism , Transforming Growth Factor beta1/pharmacology , Wound Healing/physiology
SELECTION OF CITATIONS
SEARCH DETAIL